A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis

Sara Fuchs; Tali Feferman; Roberto Meidler; Raanan Margalit; Camille Sicsic; Ningshan Wang; Kai Yun Zhu; Talma Brenner; Orgad Laub; Miriam C. Souroujon

doi:10.1016/j.jneuroim.2007.11.020

A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis

Sara Fuchs, Tali Feferman, Roberto Meidler, Raanan Margalit, Camille Sicsic, Ningshan Wang, Kai Yun Zhu, Talma Brenner, Orgad Laub, Miriam C. Souroujon

Life Sciences discipline

Research output: Contribution to journal › Article › peer-review

Abstract

Intravenous immunoglobulin (IVIG) treatment is beneficially used in autoimmune disorders including myasthenia gravis (MG) although its mode of action and active components are still not fully identified. In an attempt to isolate from IVIG a disease-specific suppressive fraction, IVIG was passed on columns of IgG from rats with experimental autoimmune MG (EAMG) or from MG patients. These chromatographies resulted in depletion of the suppressive activity of IVIG on rat EAMG whereas the minute amounts of IgG fractions eluted from the EAMG- or MG-specific columns retained the immunosuppressive activity of IVIG. These results demonstrate that a minor disease-specific immunoglobulin fraction present in IVIG is essential for its suppressive activity.

Original language	English
Pages (from-to)	89-96
Number of pages	8
Journal	Journal of Neuroimmunology
Volume	194
Issue number	1-2
DOIs	https://doi.org/10.1016/j.jneuroim.2007.11.020
State	Published - Feb 2008

Bibliographical note

Funding Information:
This research was supported by grants from The Muscular Dystrophy Association of America (MDA), The European Commission (EC, No QLG1-CT-2001-10918, QLRT-2001-00225 and LSHN-CT-2006-037833) and The Wood–Byer Foundation.

Keywords

Disease-specific anti-antibodies
Experimental autoimmune myasthenia gravis (EAMG)
IVIG (intravenous immunoglobulin) therapy
Myasthenia gravis (MG)

Access to Document

10.1016/j.jneuroim.2007.11.020

Cite this

Fuchs, S., Feferman, T., Meidler, R., Margalit, R., Sicsic, C., Wang, N., Zhu, K. Y., Brenner, T., Laub, O., & Souroujon, M. C. (2008). A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis. Journal of Neuroimmunology, 194(1-2), 89-96. https://doi.org/10.1016/j.jneuroim.2007.11.020

@article{0a8e6bc1376e42c8bf0900b4b3df55b5,

title = "A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis",

abstract = "Intravenous immunoglobulin (IVIG) treatment is beneficially used in autoimmune disorders including myasthenia gravis (MG) although its mode of action and active components are still not fully identified. In an attempt to isolate from IVIG a disease-specific suppressive fraction, IVIG was passed on columns of IgG from rats with experimental autoimmune MG (EAMG) or from MG patients. These chromatographies resulted in depletion of the suppressive activity of IVIG on rat EAMG whereas the minute amounts of IgG fractions eluted from the EAMG- or MG-specific columns retained the immunosuppressive activity of IVIG. These results demonstrate that a minor disease-specific immunoglobulin fraction present in IVIG is essential for its suppressive activity.",

keywords = "Disease-specific anti-antibodies, Experimental autoimmune myasthenia gravis (EAMG), IVIG (intravenous immunoglobulin) therapy, Myasthenia gravis (MG)",

author = "Sara Fuchs and Tali Feferman and Roberto Meidler and Raanan Margalit and Camille Sicsic and Ningshan Wang and Zhu, {Kai Yun} and Talma Brenner and Orgad Laub and Souroujon, {Miriam C.}",

note = "Funding Information: This research was supported by grants from The Muscular Dystrophy Association of America (MDA), The European Commission (EC, No QLG1-CT-2001-10918, QLRT-2001-00225 and LSHN-CT-2006-037833) and The Wood–Byer Foundation.",

year = "2008",

month = feb,

doi = "10.1016/j.jneuroim.2007.11.020",

language = "אנגלית",

volume = "194",

pages = "89--96",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier",

number = "1-2",

}

Fuchs, S, Feferman, T, Meidler, R, Margalit, R, Sicsic, C, Wang, N, Zhu, KY, Brenner, T, Laub, O & Souroujon, MC 2008, 'A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis', Journal of Neuroimmunology, vol. 194, no. 1-2, pp. 89-96. https://doi.org/10.1016/j.jneuroim.2007.11.020

TY - JOUR

T1 - A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis

AU - Fuchs, Sara

AU - Feferman, Tali

AU - Meidler, Roberto

AU - Margalit, Raanan

AU - Sicsic, Camille

AU - Wang, Ningshan

AU - Zhu, Kai Yun

AU - Brenner, Talma

AU - Laub, Orgad

AU - Souroujon, Miriam C.

N1 - Funding Information: This research was supported by grants from The Muscular Dystrophy Association of America (MDA), The European Commission (EC, No QLG1-CT-2001-10918, QLRT-2001-00225 and LSHN-CT-2006-037833) and The Wood–Byer Foundation.

PY - 2008/2

Y1 - 2008/2

N2 - Intravenous immunoglobulin (IVIG) treatment is beneficially used in autoimmune disorders including myasthenia gravis (MG) although its mode of action and active components are still not fully identified. In an attempt to isolate from IVIG a disease-specific suppressive fraction, IVIG was passed on columns of IgG from rats with experimental autoimmune MG (EAMG) or from MG patients. These chromatographies resulted in depletion of the suppressive activity of IVIG on rat EAMG whereas the minute amounts of IgG fractions eluted from the EAMG- or MG-specific columns retained the immunosuppressive activity of IVIG. These results demonstrate that a minor disease-specific immunoglobulin fraction present in IVIG is essential for its suppressive activity.

AB - Intravenous immunoglobulin (IVIG) treatment is beneficially used in autoimmune disorders including myasthenia gravis (MG) although its mode of action and active components are still not fully identified. In an attempt to isolate from IVIG a disease-specific suppressive fraction, IVIG was passed on columns of IgG from rats with experimental autoimmune MG (EAMG) or from MG patients. These chromatographies resulted in depletion of the suppressive activity of IVIG on rat EAMG whereas the minute amounts of IgG fractions eluted from the EAMG- or MG-specific columns retained the immunosuppressive activity of IVIG. These results demonstrate that a minor disease-specific immunoglobulin fraction present in IVIG is essential for its suppressive activity.

KW - Disease-specific anti-antibodies

KW - Experimental autoimmune myasthenia gravis (EAMG)

KW - IVIG (intravenous immunoglobulin) therapy

KW - Myasthenia gravis (MG)

UR - http://www.scopus.com/inward/record.url?scp=39849095842&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2007.11.020

DO - 10.1016/j.jneuroim.2007.11.020

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 18178258

AN - SCOPUS:39849095842

SN - 0165-5728

VL - 194

SP - 89

EP - 96

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

IS - 1-2

ER -

A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this